VELCADE(R) (Bortezomib) for Injection Based Regimens Result in Lower Costs and Less Patient Burden Than Other Commonly Used Multiple Myeloma Treatment Regimens

VELCADE(R) (Bortezomib) for Injection Based Regimens Result in Lower Costs and Less Patient Burden Than Other Commonly Used Multiple Myeloma Treatment Regimens

Submitted by admin on December 6, 2009 - 11:09am
Source: 
istockanalyst
News Tags: 
Velcade
Multiple Myeloma
Headline: 
VELCADE(R) (Bortezomib) for Injection Based Regimens Result in Lower Costs and Less Patient Burden Than Other Commonly Used Multiple Myeloma Treatment Regimens

Do Not Allow Advertisers to Use My Personal information